loader
Please Wait
Applying Filters...

Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Certificates of Suitability (CEPs) for r0_cep_2017_239___rev_01 Active Pharmaceutical Ingredient (API) issued by the EDQM. Original Data: EDQM Database

    Client Virtual Booth
    Menu

    Hikal

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INTERMEDIATES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Send me more info on How To Grow My Business Digitally?

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 HIKAL LIMITED Bangalore IN (1)

    filter

    01 Olmesartan medoxomil (1)

    filter

    01 India (1)

    filter

    01 Withdrawn by Holder (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    HIKAL LIMITED Bangalore IN

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olmesartan medoxomil

    PDF Supplier PDF
    URL Supplier Web Content
    R0-CEP 2017-239 - Rev 01
    Withdrawn by Holder
    Chemical
    2019-10-15
    2021-11-09
    2600
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    Looking for Certificates of Suitability (CEPs) for R0-CEP 2017-239 - Rev 01 of Hikal Limited Bangalore In

    Looking for Certificates of Suitability (CEPs) for R0-CEP 2017-239 - Rev 01 of Hikal Limited Bangalore In 1

    20

    Hikal Limited Bangalore In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.

    They are recognized for Partnering with Pharmaceutical, Life Sciences, Biotech & Specialty Chemicals Companies to deliver APIs, Intermediate & R&D Services.

    One of their significant offerings is Olmesartan medoxomil, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2017-239 - Rev 01

    This Chemical Type CEP, issued on October 15, 2019, remains in force until November 09, 2021, ensuring its reliability within the pharmaceutical industry.

    Substance Number 2600 associated with this CEP further emphasizes

    Post Enquiry
    POST ENQUIRY